WallStSmart

Coca-Cola European Partners PLC (CCEP)vsYoulife Group Inc. American Depositary Shares (YOUL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola European Partners PLC generates 1027% more annual revenue ($20.90B vs $1.85B). CCEP leads profitability with a 9.3% profit margin vs 2.3%. YOUL trades at a lower P/E of 9.4x. CCEP earns a higher WallStSmart Score of 59/100 (C).

CCEP

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 3.3Quality: 4.0
Piotroski: 3/9Altman Z: 1.55

YOUL

Hold

50

out of 100

Grade: D+

Growth: 9.3Profit: 3.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCEPSignificantly Overvalued (-65.3%)

Margin of Safety

-65.3%

Fair Value

$59.08

Current Price

$95.10

$36.02 premium

UndervaluedFair: $59.08Overvalued

Intrinsic value data unavailable for YOUL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP3 strengths · Avg: 9.0/10
EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Return on EquityProfitability
22.9%9/10

Every $100 of equity generates 23 in profit

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

YOUL3 strengths · Avg: 9.3/10
P/E RatioValuation
9.4x10/10

Attractively priced relative to earnings

EPS GrowthGrowth
5300.0%10/10

Earnings expanding 5300.0% YoY

Revenue GrowthGrowth
17.7%8/10

17.7% revenue growth

Areas to Watch

CCEP4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Debt/EquityHealth
1.503/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

YOUL4 concerns · Avg: 2.5/10
Market CapQuality
$64.64M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.4%3/10

ROE of 6.4% — below average capital efficiency

Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
-4.2%1/10

Operating margin of -4.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.

Bull Case : YOUL

The strongest argument for YOUL centers on P/E Ratio, EPS Growth, Revenue Growth. Revenue growth of 17.7% demonstrates continued momentum.

Bear Case : CCEP

The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : YOUL

The primary concerns for YOUL are Market Cap, Return on Equity, Profit Margin. Thin 2.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

CCEP profiles as a value stock while YOUL is a growth play — different risk/reward profiles.

YOUL is growing revenue faster at 17.7% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor BEVERAGES - NON-ALCOHOLIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCEP scores higher overall (59/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Visit Website →

Youlife Group Inc. American Depositary Shares

CONSUMER DEFENSIVE · EDUCATION & TRAINING SERVICES · USA

Youlife Group Inc. (Ticker: YOUL) stands at the forefront of the global health and wellness sector, offering cutting-edge lifestyle products and tailored health solutions aimed at improving quality of life. The company's emphasis on sustainability and community engagement aligns effectively with the rising demand for wellness and preventative care, presenting a compelling market opportunity. With robust strategic partnerships and a steadfast focus on research and development, Youlife is well-positioned to leverage growth opportunities and generate substantial value for institutional investors navigating the evolving health landscape.

Want to dig deeper into these stocks?